| Autor: |
Gao L; Division of Hematology and Oncology, GI Oncology Program and Experimental Therapeutics., Natov NS; Division of Gastroenterology, Tufts University School of Medicine, Boston, Massachusetts, USA., Daly KP; Department of Radiology., Masud F; King Edward Medical University, Lahore., Chaudhry S; Foundation University Medical College, Rawalpindi, Pakistan., Sterling MJ; Division of Gastroenterology, Tufts University School of Medicine, Boston, Massachusetts, USA., Saif MW; Division of Hematology and Oncology, GI Oncology Program and Experimental Therapeutics. |
| Jazyk: |
angličtina |
| Zdroj: |
Anti-cancer drugs [Anticancer Drugs] 2018 Aug; Vol. 29 (7), pp. 597-612. |
| DOI: |
10.1097/CAD.0000000000000633 |
| Abstrakt: |
Pancreatic neuroendocrine tumors (PNETs) are a rare and heterogeneous group of neoplasia and differ in their clinical presentation, behavior, and prognosis based on both histological features and cancer stage at the time of diagnosis. Although small-sized tumors can be surgically resected, locally advanced and metastatic tumors confer a poor prognosis. In addition, only limited treatment options are available to the latter group of patients with PNETs, such as hormonal analogs, cytotoxic agents, and targeted therapy. In selected patients, liver-directed therapies are also used. As expected, clinicians taking care of these patients are challenged to develop an effective and comprehensive treatment strategy for their patients amid a wide variety of treatment modalities. Targeted therapy for PNETs is limited to sunitinib and everolimus. Presently, a number of clinical studies are ongoing to assess the efficacy of newer targeted agents alone and in combination with previous agents for the treatment of advanced PNETs. The authors reviewed the current treatment and also discussed the emerging agents and emphasized the need to identify biomarkers. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
